Bidding to be the go-to genomics and data partner for drug development, Sophia Genetics raises $100M
Jurgi Camblong has spent the last decade going from minor funding round to minor funding round for his startup, Sophia Genetics, adding hospitals in the UK, US, and Latin America and expanding the platform to handle more and more data. Now, Camblong says, the company has spread far enough and has now raised plenty of cash to clear one of its last hurdles.
In the sixth and largest funding round in their 9-year history, Sophia Genetics has raised $110 million to push forward its AI-based platform for genetic medicine with a renewed focus on taking their established infrastructure and using it help biopharma collect evidence and design trials. The round was led the Israeli firm aMoon and the Japanese firm Hitachi Ventures.